BREAKING NEWS

Roche breast cancer drug extends overall survival

By REUTERS

DECEMBER 8, 2012 12:05

ZURICH - Swiss pharma group Roche's drug Perjeta significantly extended the lives of women with an aggressive and incurable form of breast cancer compared to a placebo, according to new data from a late-stage study presented on Saturday.

The detailed data presented at the San Antonio Breast Cancer Symposium found that the risk of death was reduced by 34 percent in women treated with a combination treatment of the drugs Perjeta and Herceptin plus chemotherapy compared to women treated with Herceptin, chemotherapy and a placebo, Roche said.

Roche is hoping that the Perjeta combination will become the standard treatment for women with a form of cancer known as HER2-positive, which makes up about a quarter of all breast cancers and has no cure.

White House says it has 'no comment' on Israel's attack in Iran

By REUTERS

04/19/2024 09:20 PM

Gaza war forces cancelation of Tunisia's annual Jewish pilgrimage

By REUTERS

04/19/2024 08:27 PM

Israeli drones caused no damage or casualties in Isfahan- Iran FM

By REUTERS

04/19/2024 07:13 PM

Drone explodes in Metula, without sirens sounding - report

By MAARIV ONLINE

04/19/2024 07:12 PM